Venture Partners Vii L. P. Sofinnova is 10% at Trius Therapeutics Inc (TSRX). They have made 4 open-market trades across 4 companies since 2010, most recently 2014-05-22.
CIK 0001380734
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $9.4M since 2010, against 2 sales. Too few scored purchases to measure a record yet.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.